You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Braintree Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for BRAINTREE, and when can generic versions of BRAINTREE drugs launch?

BRAINTREE has nine approved drugs.

There are five US patents protecting BRAINTREE drugs.

Summary for Braintree
US Patents:5
Tradenames:10
Ingredients:9
NDAs:9

Drugs and US Patents for Braintree

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Braintree Labs SUTAB magnesium sulfate; potassium chloride; sodium sulfate TABLET;ORAL 213135-001 Nov 10, 2020 RX Yes Yes 11,638,697 ⤷  Sign Up Y ⤷  Sign Up
Braintree Labs SUFLAVE magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate FOR SOLUTION;ORAL 215344-001 Jun 15, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up
Braintree Labs SUPREP BOWEL PREP KIT magnesium sulfate; potassium sulfate; sodium sulfate SOLUTION;ORAL 022372-001 Aug 5, 2010 AA RX Yes Yes ⤷  Sign Up ⤷  Sign Up
Braintree Labs SUTAB magnesium sulfate; potassium chloride; sodium sulfate TABLET;ORAL 213135-001 Nov 10, 2020 RX Yes Yes 11,033,498 ⤷  Sign Up ⤷  Sign Up
Braintree Labs PIZENSY lactitol FOR SOLUTION;ORAL 211281-001 Feb 12, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Braintree

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Braintree HALFLYTELY bisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL 021551-003 Jul 16, 2010 7,291,324 ⤷  Sign Up
Braintree Labs SUPREP BOWEL PREP KIT magnesium sulfate; potassium sulfate; sodium sulfate SOLUTION;ORAL 022372-001 Aug 5, 2010 6,946,149 ⤷  Sign Up
Braintree AXID nizatidine SOLUTION;ORAL 021494-001 May 25, 2004 6,930,119 ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BRAINTREE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe For Oral Solution and Delayed-release Tablet 210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg (1 Tablet Regimen) ➤ Subscribe 2010-07-30
➤ Subscribe Oral Solution 17.5 g/3.13 g/1.6 g per bottle ➤ Subscribe 2010-11-08
➤ Subscribe For Oral Solution and Delayed- 210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg ➤ Subscribe 2008-01-28
➤ Subscribe Oral Solution 15 mg/mL ➤ Subscribe 2008-05-14
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.